▶ 調査レポート

非感染性黄斑浮腫治療の世界市場

• 英文タイトル:Global Market Study on Non-infectious Macular Edema Treatment: Companies to Launch Biosimilars of First Anti-VEGF Lucentis by 2020

Persistence Market Researchが調査・発行した産業分析レポートです。非感染性黄斑浮腫治療の世界市場 / Global Market Study on Non-infectious Macular Edema Treatment: Companies to Launch Biosimilars of First Anti-VEGF Lucentis by 2020 / B-PMR-JN005資料のイメージです。• レポートコード:B-PMR-JN005
• 出版社/出版日:Persistence Market Research / 2018年5月30日
• レポート形態:英文、PDF、323ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Life Sciences & Transformational Health
• 販売価格(消費税別)
  Individual(1名、印刷不可)¥524,300 (USD4,900)▷ お問い合わせ
  Multi User(5名)¥813,200 (USD7,600)▷ お問い合わせ
  Corporate User¥1,134,200 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、非感染性黄斑浮腫治療の世界市場について調べ、非感染性黄斑浮腫治療の世界規模、市場動向、市場環境、薬剤種類別(抗VEGF薬、副腎皮質ステロイド、免疫抑制剤、生物製剤、その他)分析、投与経路別(経口、非経口、局所用)分析、症状別(非感染性ブドウ膜炎に伴う黄斑浮腫、糖尿病黄斑浮腫、網膜静脈閉塞症に伴う黄斑浮腫)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・エグゼクティブサマリー
・調査手法
・非感染性黄斑浮腫治療の世界市場環境
・非感染性黄斑浮腫治療の世界市場動向
・非感染性黄斑浮腫治療の世界市場規模
・非感染性黄斑浮腫治療の世界市場規模:薬剤種類別(抗VEGF薬、副腎皮質ステロイド、免疫抑制剤、生物製剤、その他)
・非感染性黄斑浮腫治療の世界市場規模:投与経路別(経口、非経口、局所用)
・非感染性黄斑浮腫治療の世界市場規模:症状別(非感染性ブドウ膜炎に伴う黄斑浮腫、糖尿病黄斑浮腫、網膜静脈閉塞症に伴う黄斑浮腫)
・非感染性黄斑浮腫治療の世界市場:地域別市場規模・分析
・非感染性黄斑浮腫治療の北米市場規模・予測
・非感染性黄斑浮腫治療のアメリカ市場規模・予測
・非感染性黄斑浮腫治療のヨーロッパ市場規模・予測
・非感染性黄斑浮腫治療のアジア市場規模・予測
・非感染性黄斑浮腫治療の日本市場規模・予測
・非感染性黄斑浮腫治療の中国市場規模・予測
・非感染性黄斑浮腫治療のインド市場規模・予測
・関連企業情報・競争状況

Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Current expenditure on health, % of gross domestic product
Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
Annual growth rate of current expenditure on health, per capita, in real terms
Out-of-pocket expenditure, % of current expenditure on health
Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
Physicians, Density per 1000 population (head counts)
Nurses, Density per 1000 population (head counts)
Total hospital beds, per 1000 population
Curative (acute) care beds, per 1000 population
Medical technology, Magnetic Resonance Imaging units, total, per million population
Medical technology, Computed Tomography scanners, total, per million population
Research Methodology

PMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

レポート目次

1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
2.3. Primary Research – Verbatim
2.4. Global Non-infectious Macular Edema Treatment Market – Trade Overview

3. Non-infectious Macular Edema Treatment Market Overview
3.1. Patient’s Journey Through Non-infectious Uveitic Macular Edema Treatment Process
3.2. Management Flowchart For Non-infectious Uveitis Macular Edema Treatment
3.3. Patient’s Journey Through Diabetic Macular Edema Treatment Process
3.4. Management Flowchart For Diabetic Macular Edema Treatment
3.5. Patient’s Journey Through Retinal Vein Occlusion Macular Edema Treatment Process
3.6. Management Flowchart For Retinal Vein Occlusion Macular Edema Treatment
3.7. Epidemiology
3.7.1. Non-infectious Uveitis Macular Edema
3.7.2. Diabetic Macular Edema
3.7.3. Retinal Vain Occlusion with Macular Edema
3.8. Impact Analysis
3.8.1. Anti-VEGF Therapies
3.8.2. Corticosteroids
3.8.3. Immunosuppressant
3.8.4. Biologics
3.9. U.S. Key Regulations – Macular Edema
3.10. Macular Edema Drugs: U.S. FDA Regulatory Scenario
3.11. Global Macular Edema Market Pipeline Analysis
3.12. Treatment Summary
3.13. Macular Edema Treatment Market – Supply Chain Analysis
3.14. Economic and Clinical Value Measures in Pricing of Macular Edema Treatment

4. Non-infectious Macular Edema Treatment Market Opportunity Analysis
4.1. Macro-Economic Factors
4.2. Opportunity Analysis

5. Market Background
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Trends
5.2. Reimbursement Landscape
5.3. Regulatory Scenario

6. North America Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
6.2.1. U.S.
6.2.2. Canada
6.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
6.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
6.4.1. Anti-VEGF
6.4.2. Corticosteroids
6.4.3. Immunosuppressant
6.4.4. Biologics
6.4.5. Others
6.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
6.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
6.6.1. Oral
6.6.2. Parenteral
6.6.3. topical
6.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018–2026
6.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
6.8.1. Non-infectious Uveitic Macular Edema
6.8.2. Diabetic Macular Edema
6.8.3. Retinal Vein Occlusion with Macular Edema
6.9. Market Size (US$ Mn) Forecast By Indication, 2018–2026
6.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2012–2017
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacies
6.10.3. Online Pharmacies
6.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
6.12. Drivers and Restraints: Impact Analysis
6.13. Market Attractiveness Analysis
6.13.1. By Country
6.13.2. By Drug Type
6.13.3. By Route of Administration
6.13.4. By Indication
6.13.5. By Distribution Channel
6.14. Drivers and Restraints – Impact Analysis

7. Latin America Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
7.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
7.4.1. Anti-VEGF
7.4.2. Corticosteroids
7.4.3. Immunosuppressant
7.4.4. Biologics
7.4.5. Others
7.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
7.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
7.6.1. Oral
7.6.2. Parenteral
7.6.3. topical
7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018–2026
7.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
7.8.1. Non-infectious Uveitic Macular Edema
7.8.2. Diabetic Macular Edema
7.8.3. Retinal Vein Occlusion with Macular Edema
7.9. Market Size (US$ Mn) Forecast By Indication, 2018–2026
7.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2012–2017
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Online Pharmacies
7.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
7.12. Drivers and Restraints: Impact Analysis
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Drug Type
7.13.3. By Route of Administration
7.13.4. By Indication
7.13.5. By Distribution Channel
7.14. Drivers and Restraints – Impact Analysis

8. Europe Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
8.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
8.4.1. Anti-VEGF
8.4.2. Corticosteroids
8.4.3. Immunosuppressant
8.4.4. Biologics
8.4.5. Others
8.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
8.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
8.6.1. Oral
8.6.2. Parenteral
8.6.3. topical
8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018–2026
8.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
8.8.1. Non-infectious Uveitic Macular Edema
8.8.2. Diabetic Macular Edema
8.8.3. Retinal Vein Occlusion with Macular Edema
8.9. Market Size (US$ Mn) Forecast By Indication, 2018–2026
8.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Online Pharmacies
8.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
8.12. Drivers and Restraints: Impact Analysis
8.13. Market Attractiveness Analysis
8.13.1. By Country
8.13.2. By Drug Type
8.13.3. By Route of Administration
8.13.4. By Indication
8.13.5. By Distribution Channel
8.14. Drivers and Restraints – Impact Analysis

9. APAC Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
9.2.1. China
9.2.2. Australia
9.2.3. India
9.2.4. Rest of APAC
9.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
9.4.1. Anti-VEGF
9.4.2. Corticosteroids
9.4.3. Immunosuppressant
9.4.4. Biologics
9.4.5. Others
9.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
9.6.1. Oral
9.6.2. Parenteral
9.6.3. topical
9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018–2026
9.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
9.8.1. Non-infectious Uveitic Macular Edema
9.8.2. Diabetic Macular Edema
9.8.3. Retinal Vein Occlusion with Macular Edema
9.9. Market Size (US$ Mn) Forecast By Indication, 2018–2026
9.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Online Pharmacies
9.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
9.12. Drivers and Restraints: Impact Analysis
9.13. Market Attractiveness Analysis
9.13.1. By Country
9.13.2. By Drug Type
9.13.3. By Route of Administration
9.13.4. By Indication
9.13.5. By Distribution Channel
9.14. Drivers and Restraints – Impact Analysis

10. Japan Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
10.2.1. Anti-VEGF
10.2.2. Corticosteroids
10.2.3. Immunosuppressant
10.2.4. Biologics
10.2.5. Others
10.3. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
10.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
10.4.1. Oral
10.4.2. Parenteral
10.4.3. topical
10.5. Market Size (US$ Mn) Forecast By Route of Administration, 2018–2026
10.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
10.6.1. Non-infectious Uveitic Macular Edema
10.6.2. Diabetic Macular Edema
10.6.3. Retinal Vein Occlusion with Macular Edema
10.7. Market Size (US$ Mn) Forecast By Indication, 2018–2026
10.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.8.3. Online Pharmacies
10.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
10.10. Drivers and Restraints: Impact Analysis
10.11. Market Attractiveness Analysis
10.11.1. By Drug Type
10.11.2. By Route of Administration
10.11.3. By Indication
10.11.4. By Distribution Channel
10.12. Drivers and Restraints – Impact Analysis

11. MEA Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
11.2.1. GCC Countries
11.2.2. South Africa
11.2.3. Rest of MEA
11.3. Market Size (US$ Mn) Forecast By Country, 2018–2026
11.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
11.4.1. Anti-VEGF
11.4.2. Corticosteroids
11.4.3. Immunosuppressant
11.4.4. Biologics
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast By Drug Type, 2018–2026
11.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
11.6.1. Oral
11.6.2. Parenteral
11.6.3. topical
11.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018–2026
11.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
11.8.1. Non-infectious Uveitic Macular Edema
11.8.2. Diabetic Macular Edema
11.8.3. Retinal Vein Occlusion with Macular Edema
11.9. Market Size (US$ Mn) Forecast By Indication, 2018–2026
11.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
11.12. Drivers and Restraints: Impact Analysis
11.13. Market Attractiveness Analysis
11.13.1. By Country
11.13.2. By Drug Type
11.13.3. By Route of Administration
11.13.4. By Indication
11.13.5. By Distribution Channel
11.14. Drivers and Restraints – Impact Analysis

12. Forecast Factors: Relevance and Impact and Forecast Assumptions

13. Market Structure Analysis
13.1. Market Structure by Tier of Companies

14. Competition Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Company Deep Dive
14.3.1. Allergan, Plc.
14.3.1.1. Overview
14.3.1.2. Product and Infection Type Portfolio
14.3.1.3. Production Footprint
14.3.1.4. Sales Footprint
14.3.1.5. Channel Footprint
14.3.1.6. Strategy
14.3.1.6.1.1. Marketing Strategy
14.3.1.6.1.2. Product Strategy
14.3.1.6.1.3. Channel Strategy
14.3.2. Pfizer, Inc.
14.3.2.1. Overview
14.3.2.2. Product and Infection Type Portfolio
14.3.2.3. Production Footprint
14.3.2.4. Sales Footprint
14.3.2.5. Channel Footprint
14.3.2.6. Strategy
14.3.2.6.1.1. Marketing Strategy
14.3.2.6.1.2. Product Strategy
14.3.2.6.1.3. Channel Strategy
14.3.3. Novartis AG
14.3.3.1. Overview
14.3.3.2. Product and Infection Type Portfolio
14.3.3.3. Production Footprint
14.3.3.4. Sales Footprint
14.3.3.5. Channel Footprint
14.3.3.6. Strategy
14.3.3.6.1.1. Marketing Strategy
14.3.3.6.1.2. Product Strategy
14.3.3.6.1.3. Channel Strategy
14.3.4. F. Hoffman – La Roche Ltd.
14.3.4.1. Overview
14.3.4.2. Product and Infection Type Portfolio
14.3.4.3. Production Footprint
14.3.4.4. Sales Footprint
14.3.4.5. Channel Footprint
14.3.4.6. Strategy
14.3.4.6.1.1. Marketing Strategy
14.3.4.6.1.2. Product Strategy
14.3.4.6.1.3. Channel Strategy
14.3.5. AbbVie Inc.
14.3.5.1. Overview
14.3.5.2. Product and Infection Type Portfolio
14.3.5.3. Production Footprint
14.3.5.4. Sales Footprint
14.3.5.5. Channel Footprint
14.3.5.6. Strategy
14.3.5.6.1.1. Marketing Strategy
14.3.5.6.1.2. Product Strategy
14.3.5.6.1.3. Channel Strategy
14.3.6. Bayer AG
14.3.6.1. Overview
14.3.6.2. Product and Infection Type Portfolio
14.3.6.3. Production Footprint
14.3.6.4. Sales Footprint
14.3.6.5. Channel Footprint
14.3.6.6. Strategy
14.3.6.6.1.1. Marketing Strategy
14.3.6.6.1.2. Product Strategy
14.3.6.6.1.3. Channel Strategy
14.3.7. Valeant Pharmaceuticals Inc.
14.3.7.1. Overview
14.3.7.2. Product and Infection Type Portfolio
14.3.7.3. Production Footprint
14.3.7.4. Sales Footprint
14.3.7.5. Channel Footprint
14.3.7.6. Strategy
14.3.7.6.1.1. Marketing Strategy
14.3.7.6.1.2. Product Strategy
14.3.7.6.1.3. Channel Strategy
14.3.8. Alimera Sciences Inc.
14.3.8.1. Overview
14.3.8.2. Product and Infection Type Portfolio
14.3.8.3. Production Footprint
14.3.8.4. Sales Footprint
14.3.8.5. Channel Footprint
14.3.8.6. Strategy
14.3.8.6.1.1. Marketing Strategy
14.3.8.6.1.2. Product Strategy
14.3.8.6.1.3. Channel Strategy
14.3.9. Clearside Biomedical, Inc.
14.3.9.1. Overview
14.3.9.2. Product and Infection Type Portfolio
14.3.9.3. Production Footprint
14.3.9.4. Sales Footprint
14.3.9.5. Channel Footprint
14.3.9.6. Strategy
14.3.9.6.1.1. Marketing Strategy
14.3.9.6.1.2. Product Strategy
14.3.9.6.1.3. Channel Strategy
14.3.10. Amgen, Inc.
14.3.10.1. Overview
14.3.10.2. Product and Infection Type Portfolio
14.3.10.3. Production Footprint
14.3.10.4. Sales Footprint
14.3.10.5. Channel Footprint
14.3.10.6. Strategy
14.3.10.6.1.1. Marketing Strategy
14.3.10.6.1.2. Product Strategy
14.3.10.6.1.3. Channel Strategy

15. Global Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026, By Region
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2017
15.3. Market Size (US$ Mn) Forecast By Region, 2018–2026
15.3.1. North America
15.3.2. Latin America
15.3.3. Europe
15.3.4. APAC
15.3.5. Japan
15.3.6. Middle East and Africa (MEA)
15.4. Market Attractiveness Analysis By Region

16. Global Non-infectious Macular Edema Treatment Analysis 2013–2017 and Forecast 2018–2026, By Drug Type
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2017
16.2.1. Anti-VEGF
16.2.2. Corticosteroids
16.2.3. Immunosuppressant
16.2.4. Biologics
16.2.5. Others
16.3. Market Size (US$ Mn) and Volume Forecast By Drug Type, 2018–2026
16.4. Market Attractiveness Analysis By Drug Type

17. Global Non-infectious Macular Edema Treatment Analysis 2013–2017 and Forecast 2018–2026, By Route of Administration
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2017
17.2.1. Oral
17.2.2. Parenteral
17.2.3. Topical
17.3. Market Size (US$ Mn) and Volume Forecast By Route of Administration, 2018–2026
17.4. Market Attractiveness Analysis By Route of Administration

18. Global Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026, By Indication
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2017
18.2.1. Non-infectious Uveitic Macular Edema
18.2.2. Diabetic Macular Edema
18.2.3. Retinal Vein Occlusion with Macular Edema
18.3. Market Size (US$ Mn) Forecast By Indication, 2018–2026
18.4. Market Attractiveness Analysis By Indication

19. Global Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026, By Distribution Channel
19.1. Introduction/Key Findings
19.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017
19.2.1. Hospital Pharmacies
19.2.2. Retail Pharmacies
19.2.3. Online Pharmacies
19.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2026
19.4. Market Attractiveness Analysis By Distribution Channel

20. Global Non-infectious Macular Edema Treatment Market Analysis 2013–2017 and Forecast 2018–2026
20.1. Market Value Share Analysis By All Segment
20.2. Y-o-Y Growth Analysis By All Segment
20.3. Absolute $ Opportunity

21. Research Methodology

List of Table

Table 01: North America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 02: North America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 03: North America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 04: North America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 05: North America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 06: Latin America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 07: Latin America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 08: Latin America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 09: Latin America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 10: Latin America Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 11: Europe Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 12: Europe Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 13: Europe Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 14: Europe Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 15: Europe Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 16: APAC Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 17: APAC Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 18: APAC Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 19: APAC Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 20: APAC Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 21: Japan Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 22: Japan Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 23: Japan Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 24: Japan Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 25: MEA Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 26: MEA Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 27: MEA Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 28: MEA Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 29: MEA Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 30: Global Non-infectious Macular Edema Treatment Market Size (US$ Mn) Analysis-2013–2017 and Forecast 2018–2026, By Region
Table 31: Global Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Type
Table 32: Global Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
Table 33: Global Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 34: Global Non-infectious Macular Edema Treatment Market Size Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel